UroGen develops and sells gel-based treatments for urinary tract cancers, including Jelmyto and Zusduri. It last closed at $27.65 on Nov 20, down 12.86% on the day. The next earnings report for URGN is expected around Mon, Mar 1, 2027. For the quarter ended Sep 2026, URGN reported EPS of -$0.03 on revenue of $89.0M, with revenue up 223.9% from a year ago. Over its last 8 reports the stock moved an average of 11.6% the session after earnings. Over the last 12 months URGN insiders bought $0 of stock on the open market and sold $4.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is URGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold URGN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on URGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
URGN · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend
The stock is 7% below its 20 day and 29% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $26.18, and the nearest resistance the Pivot at $29.04.
Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.2%/day
Key levels
$50.8152 week high+83.8%
$39.40100 day average+42.5%
$35.6050 day average+28.8%
$31.92200 day average+15.4%
$30.69Swing high (May 27)+11.0%
$30.51Pivot R1+10.3%
$29.6720 day average+7.3%
$29.04Pivot+5.0%
$27.65Last close
$26.18Pivot S1−5.3%
$26.00Swing low (Jun 1)−6.0%
$16.5052 week low−40.3%
Indicators
RSI (14)
40.00
Middle of its range
Neutral
MACD
-2.03
Above its signal line
Bullish
Stochastic
55.5
Middle of its range
Neutral
ADX (14)
35.1
Trending down
Williams %R
-62.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-14.2
Oversold below −100, overbought above 100
Neutral
Rate of change
+11.7%
Change over 10 sessions
Bullish
ATR (14)
$2.56
Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 17.9%/day
Key levels
$50.8152 week high+83.8%
$39.40100 day average+42.5%
$35.6050 day average+28.8%
$31.92200 day average+15.4%
$30.69Swing high (May 27)+11.0%
$30.51Pivot R1+10.3%
$29.6720 day average+7.3%
$29.04Pivot+5.0%
$27.65Last close
$26.18Pivot S1−5.3%
$26.00Swing low (Jun 1)−6.0%
$16.5052 week low−40.3%
Indicators
RSI (14)
38.92
Weak, oversold below 30
Neutral
MACD
-0.69
Below its signal line
Bearish
Stochastic
8.1
Near the bottom of its range
Oversold
ADX (14)
33.7
Trending down
Williams %R
-83.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-149.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.6%
Change over 10 sessions
Bearish
ATR (14)
$4.94
Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for URGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how URGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow URGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for URGNHow many large options trades hit URGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in URGN in the last 90 days.
From SEC Form 4 filings by URGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether URGN is in one of them and how their past URGN trades turned out.
UroGen is a biotechnology company based in Ra'Anana, Israel, that develops and sells treatments for urothelial cancers, which affect the lining of the urinary tract. Its products use a gel technology called RTGel, which turns from liquid to gel at body temperature so that a cancer drug can stay in the bladder or upper urinary tract for longer. Its approved products, Jelmyto and Zusduri, both contain the chemotherapy drug mitomycin, and the company is also developing an investigational oncolytic virus. Its customers are patients with these cancers and the doctors who treat them.